ABSTRACT The transmural distribution of myocardial blood flow across the left ventricles of anesthetized dogs was measured with radioactive microspheres during intracoronary infusion of the endothelium-dependent vasodilators acetylcholine (10 ,ug/min), adenosine triphosphate (ATP; 20 gg/min), and arachidonic acid (600 gg/min) and the endothelium-independent vasodilator nifedipine (5 gg/min). These compounds were administered before and after a 30 min intracoronary infusion of the phospholipase A2 inhibitor quinacrine (300 ,ug/min). Acetylcholine, ATP, and arachidonic acid produced significant (p < .05) increases in transmural blood flow and in the ratio of subendocardial to subepicardial blood flow (endo/epi) when compared with control. Infusion of quinacrine did not affect this ratio and did not block the increase in transmural blood flow produced by each agent; however, it did block the redistribution of flow to the subendocardium. In contrast, there was no change in endo/epi during intracoronary infusion of nifedipine before and after quinacrine. These results suggest that endothelium-dependent vasodilators produce a preferential increase in subendocardial perfusion via a product of unsaturated fatty acid metabolism. Circulation 76, No. 1, 191-200, 1987. THE INTIMAL ENDOTHELIUM plays an important role in modulating the vascular response to a large number of compounds. Furchgott and Zawadzkil first demonstrated the obligatory role of endothelium in the vasodilatory response to acetylcholine. In addition, it has been shown that adenosine triphosphate (ATP) and arachidonic acid produce endothelium-dependent relaxation of precontracted isolated blood vessels.2'3 In contrast, vasodilation produced by the slow-channel calcium-entry blocker nifedipine is the result of blockade of voltage-sensitive calcium channels4 and is not dependent on an intact vascular endothelium. In this study, the distribution of myocardial blood flow produced by intracoronary infusion of several endothelium-dependent vasodilators was compared with that produced by nifedipine, an endothelium-independent vasodilator.
THE INTIMAL ENDOTHELIUM plays an important role in modulating the vascular response to a large number of compounds. Furchgott and Zawadzkil first demonstrated the obligatory role of endothelium in the vasodilatory response to acetylcholine. In addition, it has been shown that adenosine triphosphate (ATP) and arachidonic acid produce endothelium-dependent relaxation of precontracted isolated blood vessels.2'3 In contrast, vasodilation produced by the slow-channel calcium-entry blocker nifedipine is the result of blockade of voltage-sensitive calcium channels4 and is not dependent on an intact vascular endothelium. In this study, the distribution of myocardial blood flow produced by intracoronary infusion of several endothelium-dependent vasodilators was compared with that produced by nifedipine, an endothelium-independent vasodilator.
Although the precise chemical nature of endothelium-derived relaxing factor (EDRF) is unknown, it has been postulated to be a derivative of arachidonic acid (or some other fatty acid) metabolism. 1'5 The phospho-lipase A2 inhibitor quinacrine (mepacrine), which interferes with fatty acid metabolism by preventing availability of these compounds for lipoxygenase and cyclooxygenase enzymes, also has been found to inhibit the endothelium-dependent relaxation of isolated arteries produced by acetylcholine in several vascular beds.1 '6 Intracoronary infusion of acetylcholine has been shown previously to produce a greater increase in blood flow to the subendocardium compared with the subepicardium.7 In contrast, vagal stimulation increased coronary blood flow uniformly across the left ventricular wall.8 These results suggest that intracoronary infusion of acetylcholine stimulates endothelial cell release of EDRF, which results in a redistribution of blood flow favoring the subendocardium.
Thus the purpose of this study was to characterize the transmural distribution of left ventricular blood flow after vasodilation produced by intracoronary infusion of several endothelium-dependent or -independent compounds and to assess the effects of phospholipase A2 inhibition on the distribution of blood flow produced by these agents.
Methods
General preparation. Adult The endothelium-dependent vasodilators selected for study consisted of a structurally unrelated group of compounds, including acetylcholine (5, 10, and 20 gg/min), ATP (10, 20, and 50 j,g/min), and arachidonic acid (0.3, 0.6, and 1.2 mg/min). The slow-channel calcium-entry blocker nifedipine (2, 5 , and 10 tg/min), an endothelium-independent vasodilator, was studied for purposes of comparison. The influence of the phospholipase A2 inhibitor quinacrine (300 ,ug/min ic), which blocks the release of EDRF, 14 on the actions of the vasodilator agents was also determined. Separate groups of animals (n = 6 to 7) were used to study each vasodilator. In each experiment, the first dose of radioactive microspheres was administered during intracoronary infusion of vehicle (control state). Intracoronary infusion of each vasodilator was then performed in increasing doses for 5 min to establish a dose-response relationship for coronary blood flow. Subsequently, the second dose of microspheres was administered at steady-state flow conditions during a 5 min intracoronary infusion of a dose of each vasodilator that produced an increase in coronary blood flow that was 50% to 80% of the peak reactive hyperemic response. The third dose of radioactive microspheres was injected at the end of a 30 min intracoronary infusion of quinacrine (300 1£g/min) to assess any direct effects of the phospholipase A2 inhibitor on regional 
Results
Hemodynamics. Hemodynamic data after intracoronary infusion of acetylcholine (10 ,ug/min), ATP (20 ,ug/min), arachidonic acid (600 ,ug/min), and nifedipine (5 ,ug/min) are summarized in tables 1 through 4, respectively. None of the compounds produced significant changes in heart rate, left ventricular and aortic pressures, or peak positive dP/dt. In contrast, all four compounds produced significant (p < .05) increases in total coronary blood flow of the drug-perfused region that were equal to 52% to 80% of the peak reactive hyperemic response. Both peak diastolic and systolic coronary blood flows were increased by all four vasodilators, but significantly (p < .05) so only in the presence of arachidonic acid and nifedipine.
Intracoronary infusion of quinacrine (300 ug/lmin) had no effect on heart rate, left ventricular and aortic pressures, or coronary blood flow. Peak positive dP/dt was reduced after infusion of quinacrine. The peak Effects of intracoronary infusion of ATP (20 ,ug (20 ,g/min) , arachidonic acid (600 ,g/ min), or nifedipine (5 ,g/min) had no effect on tissue flow in the unperfused region. In contrast, all of the vasodilators increased blood flow to the subepicardium, midmyocardium, and subendocardium and consequently produced significant increases in transmural blood flow in the drug-perfused region (figure 2). The transmural distribution of flow across the left ventricular free wall produced by acetylcholine, ATP, and arachidonic acid preferentially favored the subendocardium, thus increasing the ratio of subendocardial to subepicardial flow (endo/epi) (figure 3). Cyclooxygenase inhibition by indomethacin had no effect on the increase in endo/epi produced by arachidonic acid. In six experiments, arachidonic acid increased endo/epi from 1.01 ± 0.13 to 1.63 ± 0.18 before indomethacin and to 1.51 ± 0.16 after indomethacin. Endo/epi remained unchanged in the presence of nifedipine despite significant increases in transmural flow (figures 2 and 3).
Quinacrine produced no significant change in sub- epicardial, midmyocardial, subendocardial, or transmural blood flow in either normal or drug-perfused regions (tables 5 to 8; figure 2 ). Likewise, quinacrine produced no change in endo/epi (figure 3). Infusion of quinacrine, however, markedly inhibited the increase in subendocardial flow produced by acetylcholine, ATP, and arachidonic acid, thereby preventing the increase in endo/epi. Thus, whereas the absolute increases in overall tissue perfusion was unaffected (figure 2) , the preferential redistribution of blood flow to the subendocardium was prevented (figure 3). The increase in transmural flow produced by nifedipine was unchanged by quinacrine. No redistribution of flow occurred with quinacrine plus nifedipine.
Discussion
The purpose of this study was to characterize the regional distribution of coronary blood flow produced by the endothelium-dependent vasodilators acetylcholine, ATP, and arachidonic acid as compared with the endothelium-independent vasodilator nifedipine. The effects of phospholipase A2 inhibition on the vasodilation produced by these compounds were also investigated. The results demonstrate that endothelium-dependent compounds produce a preferential increase in subendocardial perfusion, thus increasing endo/epi. Endo/epi was unchanged by nifedipine. Blockade of this flow redistribution by quinacrine, a phospholipase A2 inhibitor, suggests that the increased endo/epi may be mediated by a product of unsaturated fatty acid metabolism.
A preferential increase in subendocardial perfusion produced by intracoronary infusion of acetylcholine has been shown previously to be caused by a specific dilator action on the subendocardial vasculature.8 Many endothelium-dependent compounds, including those used in this study, have additional mechanisms for producing direct smooth muscle relaxation. A summary is included in table 9, which illustrates the effect of various vasodilators on endo/epi. In contrast, intracoronary infusion of nifedipine, as well as several other vasodilators, has been shown to produce no change in endo/epi while significantly increasing transmural myocardial blood flow.'5 Although there were small differences in control hemodynamics between groups, 2. that intracoronary infusion of acetylcholine at the doses used in this study has no effect on regional contractility as assessed by isometric strain gauge arches or by sonomicrometry.7' 16 Similarly, Abrahamsson et al.'`have demonstrated no changes in regional segment shortening until very high doses (40 gg/min) of nifedipine were infused by the intracoronary route. In this study, peak positive dP/dt, a measure of global contractility, was unchanged by any of the vasodilators. Although dP/dt does not directly measure regional wall function, it may reflect regional changes in muscle function in these experiments, since the drugperfused territory was large enough that any changes in this region might be observed as a change in global contractility. Quinacrine had no significant effect on systemic hemodynamics but produced decreases in peak positive dP/dt in the acetylcholine-, ATP-, and nifedipinetreated groups. Despite these negative inotropic effects of quinacrine, there was no change in the distribution of myocardial blood flow (endo/epi). Infusion of quinacrine in the presence of acetylcholine, ATP, or nifedipine produced significant (p < .05) decreases in global contractility, indicating a possible additive negative inotropic effect of these compounds. However, Gross et al.`7 have demonstrated contractility to have only minimal effects on endo/epi provided left ventricular pressures were unchanged, as in this study. The regional distribution of increased blood flow produced by nifedipine was unchanged after quinacrine. Thus the selective blockade of subendocardial perfusion in the animals treated with endothelium-dependent vasodilators is most likely unrelated to any negative inotropic effects of quinacrine.
Activation of phospholipases with corresponding release of arachidonic or other unsaturated fatty acids from cellular storage sites and subsequent formation of metabolites may be the basis for endothelium-dependent relaxations.'8 Many stimuli, including chemical, hormonal, immunologic, and mechanical, are thought to activate phospholipases. The effects of quinacrine, a phospholipase A2 inhibitor,'9 on the vasodilation produced by acetylcholine, ATP, and arachidonic acid were investigated in this study and the results compared with those of nifedipine. Quinacrine has been shown previously to block endothelium-dependent vasodilation produced by acetylcholine and ATP" in rabbit aorta but not those produced by ATP in the canine femoral artery. 20 The basis for these results may be related to either species differences or altered reactivities of various vascular beds. In this study, infusion of quinacrine alone had no effect on regional myocardial CIRCULATION PELC et al. TABLE 5 Effects of acetylcholine (10 ,ug/min) on regional myocardial blood flow (ml/min/g) before and after quinacrine ( Infusion of quinacrine did not alter the peak flow measured during the reactive hyperemic response after a 20 sec total coronary artery occlusion. However, quinacrine did reduce the total flow repayment as assessed by area under the reactive hyperemia flow curve. These findings corroborate those of Kimura and Effects of ATP (20 ,ug/min) on regional myocardial blood flow (ml/min/g) before and after quinacrine (300 ,ug/min) Values expressed as mean ± SEM (n = 7).
ASignificant difference from control (p < .05). This the role of flow-mediated release of EDRF is unresolved for these compounds. The physiologic significance and pathophysiologic implications of endothelium-dependent vasodilation are subjects of current interest. Since few vasodilators have been shown to produce a selective increase in endo/epi, it may be of interest to study release of EDRF by other stimuli. For example, hypoxic or flowmediated release of EDRF may produce a similar pattern of vasodilation, providing no confounding hemodynamic alterations are also present (i.e., an increase in heart rate or reduction in diastolic pressure time).
Our results indicate that the endothelium-dependent vasodilators acetylcholine, ATP, and arachidonic acid produce an increase in endo/epi presumably via release of an endothelium-derived relaxing factor(s) that is the product of fatty acid metabolism. The compounds studied stimulate the release of EDRF via receptor stimulation (acetylcholine and ATP) or possibly by nonspecific changes in endothelial cell membrane fluidity (arachidonic acid).`The mechanism by which this release of EDRF alters transmural perfusion gradients has not been shown but is possibly related to a higher endothelial cell volume compared with smooth muscle cell volume within the microcirculation of the subendocardium rather than to factors involving the means of endothelial cell stimulation.
